Skip to main content

Meningioma

9
Pipeline Programs
13
Companies
10
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
480%
Monoclonal Antibody
120%
+ 8 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Exelixis
ExelixisCA - Alameda
2 programs
2
CabozantinibPhase 2Small Molecule1 trial
ZanzalintinibPhase 2Small Molecule1 trial
Active Trials
NCT05425004Recruiting24Est. May 2028
NCT07428616Not Yet Recruiting100Est. Sep 2029
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD2014Phase 21 trial
Active Trials
NCT03071874Unknown28Est. Jul 2024
Prevail Therapeutics
1 program
1
AbemaciclibPhase 2Small Molecule
Chimerix
ChimerixNC - Durham
1 program
1
JZP3507Phase 21 trial
Active Trials
NCT07533942Not Yet Recruiting30Est. Oct 2031
Sandoz
SandozAustria - Kundl
1 program
1
SOM230CPhase 2
Neutron Therapeutics
1 program
1
B10 L-BPA InjectionPhase 1/21 trial
Active Trials
NCT06668987Active Not Recruiting10Est. Dec 2026
Clarity Pharmaceuticals
Clarity PharmaceuticalsAustralia - Eveleigh
1 program
1
Cu-64 SARTATE and Cu-67 SARTATEPhase 1/21 trial
Active Trials
NCT03936426Completed5Est. Sep 2019
Pfizer
PfizerNEW YORK, NY
1 program
1
AvelumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03267836Terminated9Est. Apr 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Carbon Ion RadiotherapyN/A1 trial
Active Trials
NCT01166321Unknown35Est. Feb 2026
Heron Therapeutics
1 program
B10 L-BPA InjectionPHASE_1_2
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
AbemaciclibPHASE_2Small Molecule1 trial
Active Trials
NCT05940493Recruiting72Est. Sep 2030
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
ONC201PHASE_21 trial
Active Trials
NCT06012929Withdrawn0Est. Apr 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Jazz PharmaceuticalsONC201
ChimerixJZP3507
ExelixisZanzalintinib
Eli Lilly and CompanyAbemaciclib
ExelixisCabozantinib
AstraZenecaAZD2014
Neutron TherapeuticsB10 L-BPA Injection
Clarity PharmaceuticalsCu-64 SARTATE and Cu-67 SARTATE
PfizerAvelumab
Heidelberg PharmaCarbon Ion Radiotherapy

Clinical Trials (10)

Total enrollment: 313 patients across 10 trials

NCT06012929Jazz PharmaceuticalsONC201

A Study of ONC201 for Refractory Meningioma

Start: Dec 2026Est. completion: Apr 20270
Phase 2Withdrawn
NCT07533942ChimerixJZP3507

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Start: Jun 2026Est. completion: Oct 203130 patients
Phase 2Not Yet Recruiting
NCT07428616ExelixisZanzalintinib

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Start: May 2026Est. completion: Sep 2029100 patients
Phase 2Not Yet Recruiting
NCT05940493Eli Lilly and CompanyAbemaciclib

Abemaciclib in Newly Diagnosed Meningioma Patients

Start: Mar 2025Est. completion: Sep 203072 patients
Phase 2Recruiting
NCT05425004ExelixisCabozantinib

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Start: Jun 2022Est. completion: May 202824 patients
Phase 2Recruiting
NCT03071874AstraZenecaAZD2014

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Start: Oct 2017Est. completion: Jul 202428 patients
Phase 2Unknown
NCT06668987Neutron TherapeuticsB10 L-BPA Injection

A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma

Start: Oct 2024Est. completion: Dec 202610 patients
Phase 1/2Active Not Recruiting
NCT03936426Clarity PharmaceuticalsCu-64 SARTATE and Cu-67 SARTATE

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Start: Jul 2018Est. completion: Sep 20195 patients
Phase 1/2Completed
NCT03267836PfizerAvelumab

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Start: Jan 2018Est. completion: Apr 20239 patients
Phase 1Terminated
NCT01166321Heidelberg PharmaCarbon Ion Radiotherapy

Carbon Ion Radiotherapy for Atypical Meningiomas

Start: Jun 2012Est. completion: Feb 202635 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 313 patients
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.